Search

everythinglearnresearchcommunity

for

Search:↓

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Alkylating agents can kill cancer cells but may cause skin and allergic reactions.

A 68-year-old woman with lupus and blood disorders improved after increased steroids and immunoglobulin treatment.

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.

A woman with lupus developed rare skin growths that went away on their own.

The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.

Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

The man was diagnosed with stage III multiple myeloma and treated to improve kidney function.

Testing for the NUDT 15 variant is crucial before starting azathioprine, especially in Asians.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.

CTP-543 is generally safe for treating alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.

LustrivaTM improves hair thickness and reduces facial wrinkles safely.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

The committee decided not to approve the drug due to low effectiveness and high risks.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ruxolitinib can help regrow hair in severe alopecia areata.

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Clofazimine effectively treated ashy dermatosis in a patient.

Finasteride may help treat Neutrophil Actin Dysfunction by reducing LSP1 gene activity.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.